



## Prof Jörn M. Schattenberg

Director of the Metabolic Liver Research Program, University Medical Center Mainz, Germany.

Prof Schattenberg is the Director of the Metabolic Liver Research Program and the Clinical Liver Research Unit at the University Medical Center Mainz, Germany. He is a full professor of Medicine and serves on the Editorial Board of Hepatology and Alimentary Pharmacology & Therapeutics. He is a member of the executive committee of the LITMUS consortium for the validation of biomarkers in NASH. His research interests are on clinical and experimental aspects of metabolic and toxic liver injury, the development of therapeutic intervention and novel biomarkers in NASH.

### **NAFLD and metabolic comorbidities. Current understanding and perspectives**

---

#### **What you will learn:**

The multifactorial, progressive aspects of fatty liver disease:

- NAFLD and NASH are widespread worldwide.
- There is interaction between the liver and other organs in the context of metabolic disease.
- There is a higher risk of mortality when greater fibrosis is present.
- Metabolic comorbidities represent important risk factors for the development and prognosis of NAFLD.
- Differences between patients could be harnessed to provide more targeted, personalized treatments for better outcomes.